|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
1R01CA196996-01
|
$398,025
|
$398,025
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-11A1
|
$2,185,000
|
$2,185,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
VHL tumor suppressor gene and the initiation of renal cell carcinoma
|
5R01CA109860-11
|
$328,499
|
$328,499
|
HSU, TIEN
|
BOSTON MEDICAL CENTER
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-29S2
|
$334,740
|
$13,390
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S1
|
$34,176
|
$684
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-02S2
|
$810,357
|
$16,207
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-02
|
$9,967,453
|
$199,349
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
5P01CA120964-09
|
$1,781,486
|
$142,519
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers
|
5U24CA160034-05
|
$3,155,021
|
$788,755
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
Cooperative Cellular Transformation by LRRK2 and MET in Renal Neoplasms
|
1R15CA192094-01
|
$295,939
|
$295,939
|
LOOYENGA, BRENDAN
|
CALVIN COLLEGE
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S1
|
$37,026
|
$741
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S2
|
$49,999
|
$1,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-25
|
$4,878,887
|
$97,578
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
$4,295
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-02
|
$1,360,245
|
$34,006
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A novel soluble receptor-based therapy for Kidney Cancer
|
5R21CA178157-02
|
$172,369
|
$172,369
|
WELFORD, SCOTT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S1
|
|
$0
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S2
|
$64,741
|
$3,884
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S3
|
$229,232
|
$13,754
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S4
|
$593,811
|
$35,629
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S5
|
$917,771
|
$55,066
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S6
|
$68,356
|
$4,101
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S7
|
$778,576
|
$46,715
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-02S8
|
$73,651
|
$4,419
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-02
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-02
|
$24,080,302
|
$1,444,818
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cadherin-regulated apoptosis and survival signaling in epithelial cells
|
5R01CA142647-05
|
$361,050
|
$361,050
|
HANSEN, STEEN
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Novel Role of Honokiol in Preventing Cancer during Immune Suppression
|
1R21CA191735-01A1
|
$236,488
|
$236,488
|
PAL, SOUMITRO
|
CHILDREN'S HOSPITAL CORPORATION
|
|
THE ROLE OF LIN28B IN WILMS TUMOR
|
5F31CA186444-02
|
$35,440
|
$35,440
|
YERMALOVICH, ALENA
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Regulation of MDSC function and trafficking
|
5R01CA168488-03
|
$376,829
|
$376,829
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Germline KLLN Alterations in PTEN Mutation Negative Cowden Syndrome
|
5F30CA168151-03
|
$48,120
|
$24,060
|
NIZIALEK, EMILY
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Cancer Center Support Grant
|
3P30CA006516-50S1
|
$122,500
|
$2,450
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S2
|
$50,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S3
|
$125,000
|
$2,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S4
|
$200,000
|
$4,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S5
|
$62,500
|
$1,250
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-50
|
$11,162,542
|
$223,251
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-02
|
$1,171,980
|
$43,949
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Genetic Predictors of Response to mTOR inhibitors in advanced Renal Cancer
|
1R21CA191687-01
|
$229,296
|
$229,296
|
CHOUEIRI, TONI
|
DANA-FARBER CANCER INST
|
|
The von Hippel-Lindau Tumor Suppressor Protein:Roles in Cancer and Oxygen Sensing
|
5R01CA068490-20
|
$292,284
|
$292,284
|
KAELIN, WILLIAM
|
DANA-FARBER CANCER INST
|
|
Misassembled BAF complexes in human cancer: structural and functional consequence
|
1F31CA196218-01
|
$33,646
|
$16,823
|
POYNTER, STEVEN
|
DANA-FARBER CANCER INST
|
|
The function of Snf5, an epigenetic tumor suppressor
|
2R01CA113794-11
|
$369,063
|
$369,063
|
ROBERTS, CHARLES
|
DANA-FARBER CANCER INST
|
|
Dartmouth Lead Participation in NCI National Clinical Trials Network
|
5U10CA180854-02
|
$319,472
|
$15,974
|
DRAGNEV, KONSTANTIN
|
DARTMOUTH COLLEGE
|
|
Regulation of cell migration by septin 2 in renal cancer
|
5F31CA176910-02
|
$29,645
|
$29,645
|
DOLAT, LEE
|
DREXEL UNIVERSITY
|
|
NCI National Clinical Trials Network U10
|
5U10CA180857-02
|
$411,893
|
$10,297
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
Extracellular Matrix and Cell Attachment Proteins
|
5R01CA047056-35
|
$311,298
|
$77,825
|
ERICKSON, HAROLD
|
DUKE UNIVERSITY
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Partici
|
3U10CA180864-01S1
|
$70,000
|
$2,625
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Partici
|
5U10CA180864-02
|
$620,949
|
$23,286
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
EORTC HEADQUARTERS
|
5U10CA011488-45
|
$250,025
|
$5,001
|
LACOMBE, DENIS
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-02
|
$557,728
|
$27,886
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
Total relevant funding to Kidney Disease for this search: $42,998,519
|